ProCE Banner Activity

Hep B Consult: US, European, and Asia-Pacific Guideline Recommendations on Whether and How to Treat HBV

Tool

Learn guideline-based patient-specific HBV management recommendations using this Interactive Decision Support Tool.

A CCO account is required to start this tool. To create a free CCO account, click here.

Released: March 21, 2019

Expiration: March 19, 2020

No longer available for credit.

Share

Faculty

Kosh Agarwal

Kosh Agarwal, MD

Consultant Hepatologist and Transplant Physician
Institute of Liver Studies
Kings College Hospital NHS Foundation Trust
London, United Kingdom

Paul Y. Kwo

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Grace LH Wong

Grace LH Wong, MD

Professor
Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Honorary Consultant
Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
Prince of Wales Hospital
Hong Kong

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Gilead Text

Partners

AHF

ProCE Banner

ALF

ProCE Banner

Target Audience

This program is intended for physicians and other healthcare providers who provide care for patients with HBV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify whether each individual patient with chronic HBV infection is currently a candidate for treatment
  • Appropriately monitor untreated HBV patients to ensure prompt identification of change in their status such that treatment becomes appropriate
  • Select an appropriate treatment regimen for each patient based on individualized application of clinical practice guidelines

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Kosh Agarwal, MD

Consultant Hepatologist and Transplant Physician
Institute of Liver Studies
Kings College Hospital NHS Foundation Trust
London, United Kingdom

Kosh Agarwal, MD, has disclosed that he has received funds for research support from Gilead Sciences and Merck Sharp & Dohme and consulting fees from Arbutus, Gilead Sciences, and Vir Biotechnology.

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Paul Y. Kwo, MD, has disclosed that he has received funds for research support from Assembly, Bristol-Myers Squibb, and Gilead Sciences; has served as an advisory board member for AbbVie, Arrowhead, Bristol-Myers Squibb, Gilead Sciences, and Quest; and has served as a data and safety monitoring board member for Johnson & Johnson.

Grace LH Wong, MD

Professor
Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Honorary Consultant
Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
Prince of Wales Hospital
Hong Kong

Grace LH Wong, MD, has disclosed that she has received funds for research support from Gilead Sciences; consulting fees from Gilead Sciences and Janssen; and fees for non-CME/CE services from Abbott, AbbVie, Bristol-Myers Squibb, Echosens, Furui, Gilead Sciences, Janssen, and Roche.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.

Anna Poppa,

Managing Editor, HIV
Clinical Care Options, LLC

Anna Poppa has no relevant conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately  hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 21, 2019, through March 19, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Enter patient details and submit case.
4. Review the patient case online or printed out.
5. Submit answers to the Clinical Implications questions and evaluation questions online.

You must respond to all Clinical Implications and evaluation questions to receive credit. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve participants’ competence in identifying candidates for HBV therapy and monitoring and managing individuals with HBV infection.